Consino Bio inhalation COVID-19 vaccine arrives in Morocco

The first batch of Kvessa ® Bio-inhalation COVID-19 vaccine has arrived in Morocco, providing an innovative solution for local COVID-19 prevention. The successful launch of the inhaled COVID-19 vaccine will further accelerate the company's global commercialization process and contribute to global public health.

Morocco is the second country in the world after China to approve and purchase the Cosino bio inhalation vaccine. A Moroccan government official said that since the outbreak of COVID-19, Morocco and China have worked together in times of difficulty. Innovative inhalation vaccines with good safety and immunogenicity will help local epidemic prevention and control.

Morocco is located at the "crossroads" of the Mediterranean Sea and the Atlantic Ocean, Europe and Africa, and is an important member of the United Nations, the World Trade Organization and other major international institutions.

In recent years, China-Moldova strategic partnership has been continuously deepened. In January 2022, Morocco signed the Belt and Road Cooperation Plan with the Chinese government, becoming the first country in North Africa to sign the plan with China.

As the world's first "oral inhalation" vaccine, Covisa ® Wuyou ® is the first COvisa vaccine that can be used in the process of vaccination without needling and can be effectively protected with one breath and one breath. It establishes the first line of defense in the human respiratory tract, stimulates the triple immunity of mucous membrane, humoral fluid and cell, and has a stronger ability to deal with variants such as Omicrone. Can provide better protection for the species.

Clinical studies [1] showed that based on 2 doses of inactivated vaccine, the level of neutralizing antibody against Omicron variant was 14 times that of homologous enhancement of inactivated vaccine and 6 times that of sequential enhancement of recombinant protein vaccine. Neutralizing antibodies can last for more than 12 months [2].

In addition, Kvisa ® Mist Superior ® also has the advantages of stable storage and transportation at 2-8℃, enabling more efficient large-scale deployment and good accessibility. The innovative vaccine was authorized for emergency use by China and Morocco in 2022, and has been carried out large-scale vaccination in China.

Concino Bio will continue to strengthen its cooperation with overseas countries, promote vaccination, and continue to develop innovative, high-quality and accessible vaccine products, so as to make a positive contribution to global public health.